| Bioactivity | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1]. |
| Invitro | Trastuzumab duocarmazine (SYD985) (0.0001-100 μg/mL, 24 h) 对 HER2- 和 HER2+ 细胞都有杀伤力，与作用于 T-DM1 的 IC50 值为 0.096 μg/mL 相比，对 HER2/NEU3+ 细胞系的杀伤力要高出 7 倍，IC50值为 0.013 μg/mL。更重要的是，在 HER2/NEU1+ 细胞中，它的杀伤力是 T-DM1 的 54 倍[1]。 |
| In Vivo | Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) 均可以显著抑制肿瘤的生长，延长小鼠的生存周期，具有有效的体内抗肿瘤活性[1]。 |
| Name | Trastuzumab duocarmazine |
| CAS | 1642152-40-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. |